CTOs on the Move


 
Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.enanta.com
  • 500 Arsenal Street
    Watertown, MA USA 02472
  • Phone: 617.607.0800

Executives

Name Title Contact Details

Similar Companies

Calliditas Therapeutics AB

Developing high-value, global products for patients with significant unmet medical needs in niche indications

Bausch Health Companies

Bausch Health Companies Inc. is a multinational specialty pharmaceutical company based in Laval, Canada.

Star Medical RX (A Division of Apria Healthcare)

Star Medical RX (A Division of Apria Healthcare) is a Riverside, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ORIC Pharmaceuticals

ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including chemotherapy, immunotherapy, and anti-hormonal therapy—and across multiple cancers. The resulting product candidate, ORIC-101, is now being studied in clinical trials for a range of solid tumors. ORIC-101 and other pipeline programs are a result of rigorous, hands-on experimentation and medicinal chemistry efforts led by our internal team of scientists in biology, medicinal chemistry, DMPK and translational medicine, with assistance from academic collaborators and continued guidance from our founders and board members. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance.

Genactis

Genactis is a Fort Washington, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.